Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir and what is the scope of freedom to operate?
Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir has six hundred and twenty-one patent family members in fifty-four countries.
Summary for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
International Patents: | 621 |
US Patents: | 17 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
DailyMed Link: | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
US Patents and Regulatory Information for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Expired US Patents for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 101163479 | Solid pharmaceutical dosage formulation | ⤷ Try a Trial |
Uruguay | 34401 | MÉTODOS PARA EL TRATAMIENTO DE HCV | ⤷ Try a Trial |
Spain | 2677644 | ⤷ Try a Trial | |
South Korea | 20140143152 | ANTI-VIRAL COMPOUNDS | ⤷ Try a Trial |
Japan | 2012136546 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITOR | ⤷ Try a Trial |
Portugal | 2368890 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2368890 | PA2015012,C2368890 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: OMBITASVIRAS; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
2692346 | 132017000122534 | Italy | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(MAVIRET); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1213, 20170728 |
2203431 | CA 2015 00014 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115 |
2203431 | 2015/009 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
2340029 | CR 2015 00013 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150119 |
2692346 | LUC00038 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |